Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Anti-tumor necrosis factor α: originators <i>versus</i> biosimilars, comparison in clinical response assessment in a multicenter cohort of patients with inflammatory arthropathies

Objective. To compare etanercept and adalimumab biosimilars (SB4 and ABP501) and respective bioriginators in terms of safety and efficacy in a real-life contest. Methods. We consequently enrolled patients affected by rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, treated w...

Full description

Bibliographic Details
Main Authors: C. Gioia, A. Picchianti Diamanti, R. Perricone, M.S. Chimenti, A. Afeltra, L. Navarini, A. Migliore, U. Massafra, V. Bruzzese, P. Scolieri, C. Meschini, M. Paroli, R. Caccavale, P. Scapato, R. Scrivo, F. Conti, B. Laganà, M. Di Franco
Format: Article
Language:English
Published: PAGEPress Publications 2023-12-01
Series:Reumatismo
Subjects:
Biosimilars
bioriginators
anti-TNF
inflammatory arthropathies
Online Access:https://www.reumatismo.org/index.php/reuma/article/view/1602

Internet

https://www.reumatismo.org/index.php/reuma/article/view/1602

Similar Items